These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 34587552)
21. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Wiedmeier-Nutor JE; Iqbal M; Rosenthal AC; Bezerra ED; Garcia-Robledo JE; Bansal R; Johnston PB; Hathcock M; Larsen JT; Bergsagel PL; Wang Y; Reeder CB; Leis JF; Fonseca R; Palmer JM; Gysbers BJ; Mwangi R; Warsame RM; Kourelis T; Hayman SR; Dingli D; Kapoor P; Kumar SK; Durani U; Villasboas JC; Paludo J; Bennani NN; Nowakowski G; Ansell SM; Castro JE; Kharfan-Dabaja MA; Lin Y; Vergidis P; Murthy HS; Munoz J Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):456-462. PubMed ID: 37003846 [TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101). Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA medRxiv; 2024 Jan; ():. PubMed ID: 38343800 [TBL] [Abstract][Full Text] [Related]
23. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Wudhikarn K; Perales MA Bone Marrow Transplant; 2022 Oct; 57(10):1477-1488. PubMed ID: 35840746 [TBL] [Abstract][Full Text] [Related]
24. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature. Mercadal S; Gomez CA; Lee CJ; Couriel DR Ann Hematol; 2023 Jul; 102(7):1837-1843. PubMed ID: 37246975 [TBL] [Abstract][Full Text] [Related]
25. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV. Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335 [TBL] [Abstract][Full Text] [Related]
26. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose. Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042 [TBL] [Abstract][Full Text] [Related]
27. Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. Wat J; Barmettler S J Allergy Clin Immunol Pract; 2022 Feb; 10(2):460-466. PubMed ID: 34757064 [TBL] [Abstract][Full Text] [Related]
28. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D Front Immunol; 2021; 12():652223. PubMed ID: 34367128 [TBL] [Abstract][Full Text] [Related]
29. Impact of COVID-19 monoclonal antibodies on outcomes of COVID-19 infection in hematopoietic stem cell transplant and chimeric antigen receptor therapy recipients. Hahn EH; Li H; Sauter CS; Mossad SB Transpl Infect Dis; 2024 Aug; 26(4):e14322. PubMed ID: 38937864 [TBL] [Abstract][Full Text] [Related]
30. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Cellular Therapy SARS-CoV-2 Infection. Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA Clin Infect Dis; 2024 Jul; 79(1):86-95. PubMed ID: 38427848 [TBL] [Abstract][Full Text] [Related]
31. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735 [TBL] [Abstract][Full Text] [Related]
33. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Banerjee R; Marsal J; Huang CY; Lo M; Thiruvengadam SK; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353 [TBL] [Abstract][Full Text] [Related]
34. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients. Murray SM; Pose E; Wittner M; Londoño MC; Schaub G; Cook J; Dimitriadis S; Meacham G; Irwin S; Lim Z; Duengelhoef P; Sterneck M; Lohse AW; Perez V; Trivedi P; Bhandal K; Mullish BH; Manousou P; Provine NM; Avitabile E; Carroll M; Tipton T; Healy S; Burra P; Klenerman P; Dunachie S; Kronsteiner B; Maciola AK; Pasqual G; Hernandez-Gea V; Garcia-Pagan JC; Lampertico P; Iavarone M; Gines P; Lütgehetmann M; Schulze Zur Wiesch J; Russo FP; Barnes E; Marjot T; J Hepatol; 2024 Jan; 80(1):109-123. PubMed ID: 37863203 [TBL] [Abstract][Full Text] [Related]
35. Toxicities following CAR-T therapy for hematological malignancies. Hernani R; Benzaquén A; Solano C Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910 [TBL] [Abstract][Full Text] [Related]
36. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765 [TBL] [Abstract][Full Text] [Related]
37. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience. Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E Front Immunol; 2022; 13():1049188. PubMed ID: 36505469 [TBL] [Abstract][Full Text] [Related]
38. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G Front Immunol; 2022; 13():863554. PubMed ID: 35711445 [TBL] [Abstract][Full Text] [Related]
39. Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel. Gordon OM; Terpilowski M; Dulman R; Keller MD; Burbelo PD; Cohen JI; Bollard CM; Dave H Pediatr Hematol Oncol; 2022 Sep; 39(6):571-579. PubMed ID: 35135442 [TBL] [Abstract][Full Text] [Related]
40. Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Tamari R; Politikos I; Knorr DA; Vardhana SA; Young JC; Marcello LT; Doddi S; Devlin SM; Ramanathan LV; Pessin MS; Dunn E; Palazzo M; Bravo CD; Papanicolaou GA; Kamboj M; Perales MA; Chung DJ; Shah GL Blood Cancer Discov; 2021 Nov; 2(6):577-585. PubMed ID: 34778798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]